Roflumilast topical foam (Arcutis)

罗氟司特泡沫剂（Arcutis）

Report date: 2025/10/24 20:00:54

Base Information

Drug NameRoflumilast topical foam (Arcutis)
Drug Alias Name罗米司特泡沫剂（Arcutis）罗弗司特泡沫剂（Arcutis）罗氟斯特泡沫剂（Arcutis）ZORYVEZORYVE topical foam +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPlaque psoriasisPsoriasisDermatitis, Seborrheic +[4] 
Global Approved IndicationsDermatitis, Seborrheic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/12/15
Country/TerritoryBulgariaCanadaUnited States +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArcutis Inc
China Registration ClassN/A

Develop Information

Active CompaniesArcutis Biotherapeutics IncSato Pharmaceutical Co LtdDpt Laboratories Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisDermatitis, Seborrheic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeR03DX07
Related LinksN/A